These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

912 related items for PubMed ID: 18088159

  • 1. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
    Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.
    Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
    [Abstract] [Full Text] [Related]

  • 2. Burden of illness of neovascular age-related macular degeneration in Canada.
    Cruess A, Zlateva G, Xu X, Rochon S.
    Can J Ophthalmol; 2007 Dec; 42(6):836-43. PubMed ID: 18026200
    [Abstract] [Full Text] [Related]

  • 3. [Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].
    Pauleikhoff D, Scheider A, Wiedmann P, Gelisken F, Scholl HP, Roider I, Mohr A, Zlateva G, Xu X.
    Ophthalmologe; 2009 Mar; 106(3):242-51. PubMed ID: 18709375
    [Abstract] [Full Text] [Related]

  • 4. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study.
    Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Monès J, Xu X, Zlateva G, Buggage R, Conlon J, Goss TF.
    Arch Ophthalmol; 2007 Sep; 125(9):1249-54. PubMed ID: 17846366
    [Abstract] [Full Text] [Related]

  • 5. [Humanistic burden and health resource utilization among neovascular age-related macular degeneration patients in France].
    Soubrane G, Zlateva G, Xu X, Buggage R, Kosa M.
    J Fr Ophtalmol; 2008 Feb; 31(2):138-45. PubMed ID: 18401314
    [Abstract] [Full Text] [Related]

  • 6. Burden of illness of bilateral neovascular age-related macular degeneration in Spain.
    Ruiz-Moreno JM, Coco RM, García-Arumí J, Xu X, Zlateva G.
    Curr Med Res Opin; 2008 Jul; 24(7):2103-11. PubMed ID: 18547463
    [Abstract] [Full Text] [Related]

  • 7. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study.
    Lotery A, Xu X, Zlatava G, Loftus J.
    Br J Ophthalmol; 2007 Oct; 91(10):1303-7. PubMed ID: 17504847
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ, Ortega A, García-Layana A, Giráldez J.
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Social/economic costs and health-related quality of life in patients with histiocytosis in Europe.
    Iskrov G, Astigarraga I, Stefanov R, López-Bastida J, Linertová R, Oliva-Moreno J, Serrano-Aguilar P, Posada-de-la-Paz M, Schieppati A, Taruscio D, Péntek M, von der Schulenburg JM, Kanavos P, Chevreul K, Persson U, Fattore G, BURQOL-RD Research Network.
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():67-78. PubMed ID: 27042831
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.
    Lafuma A, Brézin A, Lopatriello S, Hieke K, Hutchinson J, Mimaud V, Berdeaux G.
    Pharmacoeconomics; 2006 Apr; 24(2):193-205. PubMed ID: 16460138
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.
    Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP.
    Value Health; 2008 Apr; 11(4):563-74. PubMed ID: 18179676
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES.
    Brown MM, Brown GC, Lieske HB, Tran I, Turpcu A, Colman S.
    Retina; 2016 Feb; 36(2):285-98. PubMed ID: 26428606
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Social/economic costs and quality of life in patients with haemophilia in Europe.
    Cavazza M, Kodra Y, Armeni P, De Santis M, López-Bastida J, Linertová R, Oliva-Moreno J, Serrano-Aguilar P, Posada-de-la-Paz M, Taruscio D, Schieppati A, Iskrov G, Gulácsi L, von der Schulenburg JM, Kanavos P, Chevreul K, Persson U, Fattore G, BURQOL-RD Research Network.
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():53-65. PubMed ID: 27048374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.